Abstract
CF101 is an A3 adenosine receptor agonist that functions as an anti-inflammatory agent. Researchers previously demonstrated its therapeutic potential to suppress inflammatory manifestations and prevent tissue damage in experimental animal models of arthritis, inflammatory bowel disease, osteoarthritis, and septic peritonitis. Phase 2a clinical study in patients with rheumatoid arthritis demonstrated the drug was apparently safe, well-tolerated, and helped improve disease signs and symptoms. In this Phase 2 study, Avni et al (p.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
